<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295863</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-1718</org_study_id>
    <nct_id>NCT04295863</nct_id>
  </id_info>
  <brief_title>Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers</brief_title>
  <official_title>A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized research study of drugs nivolumab and pembrolizumab in patients with locally
      advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs
      can be given less often then the currently approved schedule. This trial will compare drug
      levels from the blood from standard interval dosing levels versus taking the drugs less
      often.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">April 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Noninferiority margin of extended interval dosing compared to standard dosing</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the noninferiority of pharmacokinetic success, defined as drug trough levels above the target concentration of 1.5 Âµg/mL. Evaluable patients will be categorized as success or failure for this primary objective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the efficacy of extended interval and standard interval dosing</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the correlation of extended interval and standard interval dosing, as based on a combination of time-to-treatment discontinuation (TTD) and overall survival (OS). This secondary analysis will include all patients who received at least one dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>standard interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>extended interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Standard</intervention_name>
    <description>For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks</description>
    <arm_group_label>standard interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Standard</intervention_name>
    <description>For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks</description>
    <arm_group_label>standard interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Extended</intervention_name>
    <description>For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks</description>
    <arm_group_label>extended interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Extended</intervention_name>
    <description>For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks</description>
    <arm_group_label>extended interval dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advandced or metastatic cancer whose physician has determined
             they are candidates for treatment with nivolumab or pembrolizumab

          -  18 years old or older

          -  Measurable disease per RECIST criteria

        Exclusion Criteria:

          -  Patients who have previously received immune checkpoint inhibitors or investigational
             monoclonal antibody therapy.

          -  Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal
             antibody in combination with either nivolumab or pembrolizumab.

               -  Ipilimumab and nivolumab combination are not eligible for this trial.

               -  (Note: Patients whose planned treatment is the combination of anti-PD-1 and
                  tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of
                  traditional cytotoxic chemotherapy and anti-PD-1 are eligible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ratain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Ratain, MD</last_name>
    <phone>773-702-4400</phone>
    <email>mratain@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Ratain, MD</last_name>
      <phone>773-702-4400</phone>
      <email>mratain@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Ratain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

